BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
Authors:
- Marinus Van HulstMHMarinus Van Hulst
- Gijs A.A. HubbenGHGijs A.A. Hubben
- Kwamena W.C. SagoeKSKwamena W.C. Sagoe
- Charupon PromwongCPCharupon Promwong
- Parichart PermpikulPPParichart Permpikul
- Ladda FongsatitkulLFLadda Fongsatitkul
- Diarmuid M. GlynnDGDiarmuid M. Glynn
- Cees T. Smit SibingaCSCees T. Smit Sibinga
- Maarten J. PostmaMPMaarten J. Postma
- 1 December 2009
- journal article
- Published by Wiley in Transfusion
- Vol. 49 (12) , 2729-2742
Abstract
The goal of our research was to actively involve decision makers in the economic assessment of screening strategies in their region. This study attempted to accomplish this by providing an easy-to-use Web interface at http://www.bloodsafety.info that allows decision makers to adapt this model to local conditions. The cost-effectiveness was compared of 1) adding antigen screening to antibody screening for hepatitis C virus (HCV) and human immunodeficiency virus (HIV); 2) adding nucleic acid amplification testing (NAT) on hepatitis B virus (HBV), HCV, and HIV in minipool (pool of 6 [MP6] and 24 [MP24]) to antibody screening and hepatitis B surface antigen (HBsAg) screening; and 3) individual-donation NAT on HBV, HCV, and HIV to antibody screening and HBsAg screening for Ghana, Thailand, and the Netherlands. The combination of HCV antibody-antigen combination (combo) and HIV combo added to antibody screening in Ghana and Thailand was cost-effective according to the WHO criteria. MP24-NAT screening in Ghana was also cost-effective. MP24-NAT on HBV, HCV, and HIV was not cost-effective compared to the other screening strategies evaluated for the Netherlands. Large regional differences in cost-effectiveness were found for Thailand. The young transfusion recipient population of Ghana in combination with a high risk of viral transmission yields better cost-effectiveness for additional tests. The advanced age of the transfused population of the Netherlands and a small risk of viral transmission gives poor cost-effectiveness for more sensitive screening techniques. It was demonstrated that a global health economic model combined with a Web interface can provide easy access to risk assessment and cost-effectiveness analysis.Keywords
This publication has 44 references indexed in Scilit:
- Cost‐effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the NetherlandsTransfusion, 2009
- Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti‐HCV, anti‐HIV, and p24/anti‐HIV combination assays in seroconversion panelsTransfusion, 2009
- Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern ThailandTransfusion, 2007
- Viral hepatitis infections among dialysis patients: Thailand registry reportNephrology, 2007
- Transfusion in sub-Saharan Africa: does a Western model fit?Journal of Clinical Pathology, 2007
- A survey of the demographics of blood useTransfusion Medicine, 2007
- Costs and benefits of bacterial culturing and pathogen reduction in the NetherlandsTransfusion, 2006
- Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing?Transfusion, 2005
- Update of Cost-effectiveness Analysis for Solvent-Detergent-Treated PlasmaJAMA, 1999
- Potential deferral criteria predictive of human immunodeficiency virus positivity among blood donors in ThailandTransfusion, 1994